Furthermore, since EphA2 is overexpressed in ovarian serous carcinoma and is associated with poor clinical outcomes [18], it is possible that the combination therapy with Epha2 inhibition may be a viable option for further improving clinical outcomes of patients with other histological subtypes such as serous carcinoma. Here, EPHA2 is linked to serous adenocarcinoma.